Financial Performance - The company reported a basic earnings per share of -0.2200 yuan for 2024, a significant decrease of 1000% compared to -0.0200 yuan in 2023 [1] - The net profit for 2024 was -0.24 billion yuan, down from -0.02 billion yuan in 2023, reflecting a decline of 1100% [1] - Operating revenue decreased by 23.6% to 1.23 billion yuan in 2024 from 1.61 billion yuan in 2023 [1] - The return on equity was -7.84% in 2024, a drastic drop from -0.62% in 2023 [1] Shareholder Information - The top ten unrestricted shareholders collectively hold 31.9868 million shares, accounting for 46.06% of the circulating shares, with a decrease of 864,300 shares compared to the previous period [1] - Key shareholders include Yan Heping with 13.3115 million shares (19.17% of total shares) and Hao Equity Investment Center with 7.9840 million shares (11.50%), both showing no change [2] - Notable exits from the top ten shareholders include Shenzhen Zeyuan Private Securities Fund Management and Yu Tao, indicating a shift in shareholder composition [2]
大禹生物:2024年报净利润-0.24亿 同比下降1100%